BAILII is celebrating 24 years of free online access to the law! Would you consider making a contribution?
No donation is too small. If every visitor before 31 December gives just £1, it will have a significant impact on BAILII's ability to continue providing free access to the law.
Thank you very much for your support!
 |
[Home] [Databases] [World Law] [Multidatabase Search] [Help] [Feedback] | |
United Kingdom Intellectual Property Office Decisions |
||
|
You are here: BAILII >> Databases >> United Kingdom Intellectual Property Office Decisions >> GW Pharma Limited (Patent) [2012] UKIntelP o23712 (19 June 2012) URL: http://www.bailii.org/uk/cases/UKIntelP/2012/o23712.html Cite as: [2012] UKIntelP o23712 |
||
[New search] [Printable PDF version] [Help]
Summary
The application relates to the use of one or more phytocannabinoids selected from cannabidiol (CBD), cannabigerol (CBG) and cannabidiolic acid (CBDA) to prevent or treat cancer of the prostate where TRPM8 activity is essential for the cancers survival. The applicant argued that, in assessing support for a second medical use claim, one could combine the state of the art at the filing date with the data present in an application as originally filed to provide adequate support. The Hearing Officer found that the specification as filed did not provide the support for the claimed medical use (as decided in Prendergast’s Applications [2000] RPC 446) and that the objection could not be overcome by the subsequent filing of evidence. The Hearing Officer also found that the claim was unclear but, insofar as it could be understood, was defined by a mechanism of action and therefore amounted to a discovery. The application was refused.
